AMD drug reimbursement pressure rising in US
This article was originally published in Scrip
European pricing and reimbursement pressure for anti-VEGF therapies that treat age-related macular degeneration (AMD) and diabetic macular edema (DME) has been well documented over the past several months, but similar pressure is building in the US where Eylea (aflibercept) and Lucentis (ranibizumab) are seen by retina specialists as the most effective treatment options.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.